News Search Results
Mar 03, 2026, 09:04 ET CenExel Clinical Research Network Expands Capabilities Across Sites Nationwide
psychedelic dosing room and Schedule I drug storage roomInfusion capabilitiesAccess to top-rated imaging vendorsDedicated CNS prescreening and intake spaceState-of-the-art pharmacy and laboratory facilitiesFull patient kitchen, dining area and common spacesThe
More news about: CenExel Clinical Research
Mar 03, 2026, 09:00 ET Shareholders that lost money on REGENXBIO Inc.(RGNX) should contact The Gross Law Firm about pending Class Action - RGNX
press release announcing that the FDA placed a clinical hold on its investigational gene therapy RGX-111. Defendants announced that an intraventricular CNS tumor was found in a participant treated in its RGX-111 Phase I/II study. Following this news, the price of REGENXBIO's common stock declined from a
More news about: The Gross Law Firm
Mar 03, 2026, 06:30 ET Immunic to Participate in Investor Conferences in March
[email protected] 17-18: Stifel 2026 Virtual CNS Forum. Dr. Vitt and Mr. Tardio will participate in a fireside chat on Wednesday, March 18, at 4:00 pm ET at this virtual conference. A webcast will
More news about: Immunic, Inc.
Mar 02, 2026, 17:58 ET REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses
Plaintiff alleges that in truth, defendants were aware of the serious safety issues relating to the RGX-111 study including the potential for CNS neoplasm and in November 2023 abruptly decided to de-prioritize its second-most advanced clinical candidate, RGX-111, and seek "strategic alternatives"
More news about: Robbins LLP
Mar 02, 2026, 16:05 ET Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
of disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases.About IBTROZI IBTROZI is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, 2025, following Priority Review and Breakthrough
More news about: Nuvation Bio Inc.
Mar 02, 2026, 16:05 ET Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
significant unmet medical need for a novel efficacious antiseizure medicine that is easy-to-use, does not burden patients with central nervous system (CNS) side effects like dizziness and somnolence, and does not make their comorbidities worse. In fact, we were very excited to report preliminary data demonstrating
More news about: Biohaven Ltd.
Mar 02, 2026, 14:46 ET The Multiple Sclerosis Association of America (MSAA) Launches Campaign Focused on Self-Advocacy Strategies in Recognition of MS Awareness Month
SclerosisMultiple sclerosis (MS) is a disease of the central nervous system (CNS), which consists of the brain, optic nerves, and spinal cord. MS damages or destroys the protective covering (known as myelin) surrounding the nerves of the CNS and can potentially injure the nerves as well. This damage causes reduced
More news about: Multiple Sclerosis Association of America
Mar 02, 2026, 09:10 ET XellSmart Receives Fourth Consecutive US FDA & China NMPA IND Clearance for MSA-P iPSC-derived Cell Therapy
patients worldwide.Standing at the Forefront of iPSC-derived Cell Therapies for CNS Diseases This pipeline extension into MSA-P naturally taps into XellSmart's expertise in CNS diseases, evidenced by its multiple cleared "China or global first" INDs. Overall, nine INDs from
More news about: XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd.
Mar 02, 2026, 08:00 ET Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities
unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis
More news about: Pulmatrix Inc.
Feb 27, 2026, 11:44 ET Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments
multimedia:https://www.prnewswire.com/news-releases/psychedelic-biotechs-push-toward-phase-3-five-companies-advancing-cns-treatments-302699781.html
More news about: Equity Insider
Feb 27, 2026, 11:28 ET Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy
Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, antiretroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms
More news about: Cipla USA Inc.
Feb 27, 2026, 09:20 ET RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for
More news about: Faruqi & Faruqi, LLP
Feb 27, 2026, 01:10 ET RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
candidate RGX-111 were overwhelmingly positive while it concealed negative data on its efficacy and safety. The Company then revealed an intraventricular CNS tumor was discovered in a participant treated as part of a RGX-111 study. Based on these facts, the Company's public statements were false and materially
More news about: The Schall Law Firm
Feb 26, 2026, 18:57 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers
Feb 26, 2026, 18:54 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers
Feb 26, 2026, 18:45 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers
Feb 26, 2026, 18:41 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers
Feb 26, 2026, 18:26 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers
Feb 26, 2026, 16:25 ET Cohen & Steers, Inc. Declares Quarterly Dividend
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- The Board of Directors of Cohen & Steers, Inc. (NYSE: CNS) declared a cash dividend for the first quarter of 2026 in the amount of $0.67 per share of common stock, representing an 8.1% increase from the $0.62
More news about: Cohen & Steers, Inc.
Feb 26, 2026, 15:17 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for
More news about: Pomerantz LLP
Feb 26, 2026, 12:07 ET Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
multimedia:https://www.prnewswire.com/news-releases/psychedelic-medicine-advances-here-are-five-companies-targeting-cns-disorders-302698691.html
More news about: USA News Group
Feb 26, 2026, 10:00 ET GEMMABio Announces First Patient Dosed in CHARISMA Trial of GB221, Investigational Next‑Generation Gene Therapy for Spinal Muscular Atrophy Type 1 (SMA1)
therapy for SMA1 delivered directly to the cerebrospinal fluid (CSF) by intracisterna‑magna (ICM) injection. Using proprietary, central nervous system (CNS) platform technology licensed from the University of Pennsylvania, GB221 was developed to express a functional, codon‑optimized SMN1 gene from
More news about: GEMMA Biotherapeutics
Feb 26, 2026, 08:05 ET Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results
unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis
More news about: Pulmatrix Inc.
Feb 25, 2026, 09:00 ET Contact Levi & Korsinsky by April 14, 2026 Deadline to Join Class Action Against REGENXBIO Inc.(RGNX)
press release announcing that the FDA placed a clinical hold on its investigational gene therapy RGX-111. Defendants announced that an intraventricular CNS tumor was found in a participant treated in its RGX-111 Phase I/II study. Following this news, the price of REGENXBIO's common stock declined from a
More news about: Levi & Korsinsky, LLP
Feb 25, 2026, 03:00 ET ARTHEx Biotech Announces Publication in The American Journal of Human Genetics Highlighting the Discovery and Preliminary Preclinical Profile of ATX-01 for Myotonic Dystrophy Type 1 (DM1)
I/IIa ArthemiR™ trial. Building on this foundation, ARTHEx is advancing a pipeline of therapies for additional areas of high unmet need across muscular, CNS and cardiac diseases.The Company headquarters are in Valencia, Spain. For more information on ArthemiR™, please visit
More news about: ARTHEx Biotech